Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has seen its stock price gain 70.97, or +96.34%, so far in 2017. In the past 3-month period alone, shares of VRTX have appreciated -3.49 – or -2.36%. The stock’s 52-week range is $71.46 to $167.85, and its 3-month range is $139.05 to $163.64.The average Wall Street analyst rating for Vertex Pharmaceuticals Incorporated is Strong Buy, according to the average of 20 analyst scores. Of those analysts, 13 rate stock as a Strong Buy, 3 rate it as Hold, and just no analyst rates it as a Moderate Sell.Insider Trading Activity for Vertex Pharmaceuticals IncorporatedInsider trading activity is a great indicator of how a stock is performing, so let’s take a look at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated has had 23 insider trades in the last 3 months, including 1 open market buys and 22 sells. Of those insider trades, 9,566 shares of Vertex Pharmaceuticals Incorporated were purchased and 293,579 shares were sold. The total number of shares traded in the last 90-day period is 303,145.
     (adsbygoogle = window.adsbygoogle || []).push({});
Insider trading over the last 12 months, however, paints a different picture. In the last year there have been a total of 113 insider trades, including 18 open market buys and 95 sells. Of those transactions, there were 221,919 shares of VRTX bought and 1.75 million shares sold. The total number of shares traded in the last 12 months is 1.97 million.The most recent open market insider trade was Automatic Sell of 221 shares on a day where the closing price was 147.29. The insider, ARBUCKLE STUART A, now holds 41,952 shares of VRTX.The most recent non open market insider trade was completed by PARINI MICHAEL on 11/03/2017, and was a acquisition of 2,330 shares with a final price of $86.52. The insider now holds 31,139 shares of Vertex Pharmaceuticals Incorporated (VRTX).Examining Institutional Ownership at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)According to Vertex Pharmaceuticals Incorporated’s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 94.19%. The total amount of shares outstanding is 253.81 million, giving the company a market capitalization of about 36.71 billion.There are 657 institutional holders with active positions, accounting for 238.21 million shares in total. Of those holders, 354 had increased positions amounting to 20.13 million shares, 226 had decreased positions amounting to 17.96 million shares, and 77 holders have a held position accounting for 200.11 million shares.According to Vertex Pharmaceuticals Incorporated (VRTX) most recent 13F filing, the company has 86 new institutional holders – accounting for 1.88 million shares of its common stock. There were 40 sold out positions, amounting to 1 million shares.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.